#### 1 Title:

2 Low daytime light and bright night-time light are associated with psychiatric disorders: an objective light study in >85,000 UK Biobank participants 3

#### 4 **Proposed Author List:**

- Angus C. Burns<sup>1,2,3</sup>, Daniel P. Windred<sup>1</sup>, Martin K. Rutter<sup>4,5</sup>, Patrick Olivier<sup>6</sup>, Céline Vetter<sup>7</sup>, 5
- Richa Saxena<sup>2,3,8</sup>, Jacqueline M. Lane<sup>2,3,9</sup>, Andrew J. K. Phillips<sup>1\*</sup>, Sean W. Cain<sup>1\*</sup> 6

#### 7 **Affiliations:**

- <sup>1</sup>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash 8 University, Melbourne, VIC, Australia; 9
- 10 <sup>2</sup>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA;
- 11 <sup>3</sup>Broad Institute, Cambridge, MA, USA;
- <sup>4</sup>Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, 12
- Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; 13
- 14 <sup>5</sup>Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation
- 15 Trust, Manchester Academic Health Science Centre, Manchester, UK.;
- 16 <sup>6</sup>Action Lab, Faculty of Information Technology, Monash University, Clayton, VIC, 17 Australia.
- 18 <sup>7</sup>Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA;
- 19 <sup>8</sup>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital 20 and Harvard Medical School, Boston, MA, 02114, USA;
- <sup>9</sup>Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, 21 22 02115, USA
- 23 \*Equal contribution

#### 24 **Corresponding Authors:**

25	Angus C. Burns (angus.burns1@monash.edu), Sean W. Cain (sean.cain@monash.edu)
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract.

## 

Circadian rhythm disturbance is a common feature of psychiatric disorders. Light is the primary input to the circadian clock, with daytime light exposure strengthening rhythms and nighttime light exposure weakening rhythms. However, the independent effects of day and night light exposure on psychiatric outcomes have not been well characterized. In this study, we performed the largest to-date cross-sectional analysis of objectively measured day and night light exposure and examined their relationship with psychiatric disorders. UK Biobank cohort participants aged 37-73 years were recruited into the UK Biobank general cohort population. In a subset of participants (n=86,772; 43% male), light and physical activity patterns were monitored for  $\sim 7$  days. Using regression models adjusted for age, sex, ethnicity, photoperiod (day length), employment, and physical activity, we examined the independent associations of day and night-time light with psychiatric disorders and measures of symptom severity. We found that greater night light exposure was associated with greater odds of major depressive disorder (MDD), generalized anxiety disorder (GAD), bipolar disorder, post-traumatic stress disorder (PTSD), self-harm behavior and psychotic experiences. Conversely, greater daytime light exposure was associated with lower odds of MDD, PTSD, self-harm behavior and psychotic experiences. There was no significant association of day light exposure with GAD or bipolar disorder. Our findings demonstrate that low day light and bright night light exposure are associated with a wide range of psychiatric outcomes. Avoiding light at night and seeking light during the day may be a simple and effective, non-pharmacological means of broadly improving mental health. 

Funding

Funded in part by the Australian Government Research Training Program and National Health and Medical Research Council (NHMRC; project number = GNT1183472).

#### 83 Introduction.

84

85 Virtually all psychiatric disorders have been associated with disrupted circadian rhythms and 86 sleep<sup>1</sup>. In humans, nearly every cell in the body contains a circadian ( $\sim$ 24-hour) clock. These clocks regulate basic cellular functions, including gene expression for >80% of the protein 87 coding genome<sup>2</sup>. The network of circadian clocks throughout the body is organized by a 88 89 central ('master') circadian clock in the suprachiasmatic nucleus (SCN) in the hypothalamus. Rhythms within the SCN are regulated by daily light exposure patterns, with direct retinal 90 91 inputs communicating light/dark information to the central circadian clock. This biological 92 system evolved under predictable conditions of bright light during the day and very dim light during the night to ensure stable, robust rhythms<sup>3</sup>. Alterations to this pattern in daily life 93 94 could contribute to adverse psychiatric outcomes.

95

96 In this study, we used objective recordings of daily light exposure data to characterize the 97 levels of light in the day and night in a sample of 86,772 UK Biobank participants. We used 98 these data to test the two primary hypotheses: (i) greater light exposure in the day is 99 associated with better psychiatric outcomes and that (ii) greater light exposure at night is 100 associated with worse psychiatric outcomes. These hypotheses were motivated by the known 101 effects of day and night light exposure on the human circadian system, and the well-102 established links between circadian disruption and psychiatric disorders. Since the circadian system is implicated in regulating virtually all areas of physiology and behavior, we 103 104 investigated a constellation of psychiatric outcomes available in the UK Biobank Mental 105 Health Questionnaire.

106

#### 107 **Results.**

108

109 Of the 103,669 UK Biobank participants that completed the actigraphy assessment, we 110 excluded those with poor quality or unreliable accelerometry, sleep, and light data (see 111 Methods for details), leaving 86,772 participants. Of these, 86,631 had complete data for day 112 and night light as well as the covariates in our fully adjusted model 3. Light in the day and 113 night showed extreme positive skew (skewness > 1 for both). As such, the day and night light 114 variables were divided into four equally sized quartiles ( $n_{O1-O4} = 21,693$ ) in ascending 115 brightness and were entered together as independent categorical predictors in all models (referent = Quartile 1, lowest brightness). Characteristics of the sample are presented in Table 116 117 1 for the lowest (Q1 & Q2) and highest (Q3 & Q4) quartiles for both day and night light 118 exposure.

119

120 The reliability of light measurements was assessed in a subset of the actigraphy sample (n =121 2,988) that completed a series of four repeated actigraphy assessments. These assessments 122 occurred on average 3.23 years (SD 0.65) after their initial assessment over the course of a 123 year with three months between each measurement. A linear mixed-effects model with a 124 crossed random effect structure including participant, assessment, and time of day was used 125 to estimate the intra-class correlation (ICC) of light. Light measurements showed good 126 reliability, ICC = 0.803.

127

128 339,092 UK Biobank participants were invited to complete the online Mental Health 129 Questionnaire (MHQ) in 2016 and 157,366 completed the questionnaire. Measurement of 130 psychiatric outcomes as part of the MHQ took place an average of 1.86 years (SD = 0.66) after the actigraphy assessment. The study sample comprised participants who completed 131 both the MHQ and actigraphy assessment and sample sizes varied depending on the outcome 132

133 variable assessed, ranging from 26,956 to 61,442 for model 1 and 26,824 to 61,147 in model 134 3.

135

136 Figure 1 shows that in fully adjusted regression models (Model 3; adjusting for age, sex, 137 ethnicity, photoperiod, physical activity and employment; see Table 2), when compared to participants in the lowest quartile of night light exposure (Q1), higher night light exposure 138 139 was associated with higher odds of lifetime major depressive disorder (Likelihood Ratio Test 140 (LRT) p < 0.0001; OR<sub>04</sub> = 1.30, 95% CI = 1.23-1.38, p < 0.0001), self-harm (LRT p < 0.0001) 141 0.0001;  $OR_{04} = 1.27, 95\%$  CI = 1.14-1.42, p < 0.0001), generalized anxiety disorder (LRT p 142 = 0.0001; OR<sub>04</sub> = 1.23, 95% CI = 1.11-1.36, p = 0.0001), PTSD (LRT p < 0.0001; OR<sub>04</sub> = 1.34, 95% CI = 1.22-1.48, p < 0.0001), and lifetime psychotic experiences (LRT p = 0.0009; 143 144  $OR_{04} = 1.21, 95\%$  CI = 1.09-1.34, p = 0.0003). There was no overall association of night 145 light exposure with lifetime bipolar disorder (LRT p = 0.18), however, the brightest night 146 light quartile was associated with increased odds of bipolar disorder ( $OR_{04} = 1.20, 95\%$  CI = 147 1.02-1.42, p = 0.03). Figure 2 shows that greater night light exposure was associated with 148 higher scores on the PHQ-9 (LRT p < 0.0001; Standardized  $\beta_{04} = 0.13$ , 95% CI = 0.11-0.15, 149 p < 0.0001), GAD-7 (LRT p < 0.0001;  $\beta_{Q4} = 0.07$ , 95% CI = 0.05-0.09, p < 0.0001), PCL-6 (LRT p < 0.0001;  $\beta_{04} = 0.11$ , 95% CI = 0.08-0.14, p < 0.0001) and lower wellbeing scores 150 151 (LRT p < 0.0001;  $\beta_{04} = -0.11$ , 95% CI = -0.13–0.08, p < 0.0001; see Supplementary Table 1). 152 The results for Model 1 (unadjusted) and Model 2 (adjusted for age, sex, ethnicity and photoperiod) were similar in terms of direction, strength and significance to Model 3. 153

154

155 Figure 1 shows that in the fully adjusted regression models, higher day light exposure (see 156 Table 3) was associated with lower odds of lifetime major depressive disorder (LRT p < 1157 0.0001;  $OR_{04} = 0.81$ , 95% CI = 0.76-0.87, p < 0.0001), self-harm (LRT p = 0.0001;  $OR_{04} =$ 158 0.76, 95% CI = 0.67-0.87, p = 0.0001), PTSD (LRT p = 0.01; OR<sub>04</sub> = 0.82, 95% CI = 0.73-0.92, p = 0.001) and psychotic experiences (LRT p < 0.0001; OR<sub>Q4</sub> = 0.69, 95% CI = 0.61-159 160 0.79, p < 0.0001). There was no association of day light exposure with generalized anxiety 161 disorder (LRT p = 0.61; OR<sub>04</sub> = 0.96, 95% CI = 0.85-1.09, p = 0.22) or lifetime bipolar 162 disorder (LRT p = 0.22; OR<sub>04</sub> = 0.86, 95% CI = 0.70-1.05, p = 0.13). Figure 2 shows that 163 greater day light exposure was associated with lower scores on the PHO-9 (LRT p < 0.0001; 164  $\beta_{04} = -0.09, 95\%$  CI = -0.12--0.07, p < 0.0001), GAD-7 (LRT p < 0.0001;  $\beta_{04} = -0.05, 95\%$ CI = -0.08--0.03, p = 0.0001), PCL-6 (LRT p = 0.002;  $\beta_{04} = -0.08$ , 95% CI = -0.12--0.04, p = 0.002165 0.0001) and higher wellbeing scores (LRT p < 0.0001;  $\beta_{04} = 0.08$ , 95% CI = 0.05-0.11, p < 0.0001166 167 0.0001; see Supplementary Table 2). The results for Model 1 (unadjusted) and Model 2 168 (adjusted for age, sex, ethnicity, and photoperiod) were similar in terms of direction and 169 significance to Model 3. However, ORs tended to be smaller in Model 3 after the addition of 170 physical activity and employment covariates. 171

#### 172 **Discussion.**

173

174 We found that objective light exposure patterns were associated with the likelihood of 175 psychiatric disorders and the severity of symptoms across a broad range of outcomes. 176 Brighter light at night was associated with a greater likelihood of depression, self-harm 177 behavior, PTSD, psychosis, generalized anxiety disorder, and mania/hypomania. Brighter 178 light in the day was associated with lower odds of depression, self-harm behavior, PTSD, and 179 psychosis. These associations were independent of demographic, physical activity, 180 photoperiod, and employment covariates.

182 The most striking results were observed for the influence of light at night on depression. For 183 individuals in the brightest night light quartile, we saw ~30% higher risk of Major Depressive Disorder. Similar results were observed for self-harm behavior, Generalized Anxiety 184 185 Disorder, and mood measured with the PHO-9. Depression has long been associated with the 186 disruption of both the timing and amplitude of circadian rhythms. Patients with depression have been found to have weakened circadian rhythms (blunted amplitude)<sup>4</sup> an effect that is 187 reversed in recovery<sup>5,6</sup>. Greater disruption of circadian timing has been associated with 188 poorer mood outcomes<sup>7,8</sup>. The severity of mood symptoms and the duration of depressive 189 episodes are greater in those who experience circadian rhythm disturbance<sup>8,9</sup> and the presence 190 191 of circadian disturbance in depression is predictive of a greater risk for recurrence $^{10,11}$ . In 192 postmortem brain tissue from patients with MDD, a profound disruption in rhythms was seen throughout the brain<sup>12</sup>. As light at night alters circadian timing and dampens circadian 193 amplitude<sup>13</sup>, our results are consistent with night light exposure as a cause of the disruption 194 195 observed in people with depression. The human circadian system is highly sensitive to light at night<sup>14</sup>, but this sensitivity is profoundly enhanced by the common antidepressant 196 citalopram<sup>15</sup>. Thus, treatment of depression with these drugs could play a causal role in 197 198 exacerbating circadian disruption. Patients with depression who tend to get more light at 199 night responded more poorly to SSRIs, switching medications more often and having more suicidal ideation<sup>16</sup>. Together, these findings point to the avoidance of light at night as an 200 201 important therapeutic target for recovery.

202

203 We found that brighter light in the day was associated with ~20% lower odds of Major 204 Depressive Disorder, less self-harm behavior, and better mood on the PHQ-9. Daytime light 205 therapy has long been shown to be efficacious in treating both seasonal and non-seasonal depression<sup>17</sup>. Light therapy has also been shown to significantly enhance treatment efficacy 206 207 with a selective serotonin reuptake inhibitor<sup>18</sup>. Our findings suggest that the use of 208 specialized light therapy boxes are not necessary for therapeutic effects of light. Our findings 209 of objective measurements of daytime light exposure are consistent with our previous finding 210 of an association of self-reported outdoor light exposure in >400.000 participants<sup>19</sup>. In that study, self-reported greater time spent outdoors during the day was associated with lower 211 212 odds of lifetime major depressive disorder, less antidepressant usage, less frequent anhedonia, greater happiness, and lower neuroticism. Those findings were independent of demographic, 213 214 lifestyle, and employment covariates and held in both cross-sectional and longitudinal 215 analyses. Thus, both large-scale objective and subjective light exposure data demonstrate the 216 beneficial effect of daytime light exposure on depression. Getting more light exposure in the 217 day, and not necessarily in the morning, could be a simple means of improving depression 218 trajectories.

219

At high levels of light exposure at night, we observed higher odds of bipolar disorder. Similar 220 to depression, bipolar disorder has long been associated with circadian disruption (for a 221 review, see<sup>20</sup>). In bipolar disorder, there is greater variability of circadian timing and a 222 223 dampened amplitude of behavioral rhythms, both of which could be indicative of circadian 224 disruption by light at night. Hypersensitivity of the circadian system to light at night has been proposed to be a trait marker of bipolar disorder<sup>21,22</sup> Drugs used to treat bipolar disorder have 225 been shown to reduce the sensitivity of the circadian system to light at night<sup>23,24</sup> suggesting 226 227 that a normalization of circadian light sensitivity may play a role in recovery by reducing the 228 effects of light at night. Increased sensitivity to light may occur at the level of the retinal 229 circadian photoreceptors (intrinsically photosensitive retinal ganglion cells; ipRGCs) that are highly sensitive to short-wavelength ("blue") light<sup>25</sup> as trait hypomania has been shown to be 230 associated with increased ipRGC responsiveness to blue light<sup>26</sup>. Consistent with this, wearing 231

blue-blocking glasses at night was found to be effective in reducing mania in patients<sup>27</sup>. We 232 233 did not see significant associations of bipolar disorder or hypomania/mania with brighter 234 daytime light. This may reflect a ceiling effect of any light in the day on an already highly 235 sensitive circadian system. For patients with episodes of mania, the avoidance of light at 236 night specifically may be beneficial.

237

238 We found both an adverse association of nighttime light exposure and a beneficial association 239 of daytime light exposure with PTSD. In previous studies, circadian dysrhythmia has been associated with symptom severity in PTSD<sup>28</sup> and lower urinary melatonin levels after a 240 241 trauma exposure have been found to predict a higher risk for PTSD<sup>29</sup>, a finding replicated in 242 military personnel<sup>30</sup>. Though it is possible that low endogenous melatonin levels may 243 produce this increased PTSD vulnerability, our results suggest bright night light exposure 244 and/or high circadian light sensitivity may be antecedent factors leading to blunted and 245 disrupted rhythms. This is supported by evidence that melatonin and phase advancing daytime light may be effective treatments for PTSD symptoms<sup>31,32</sup>. Furthermore, we have 246 recently demonstrated that PTSD is genetically correlated with greater light sensitivity<sup>33</sup>. The 247 248 avoidance of light at night and seeking bright daytime light after trauma may reduce the 249 likelihood of developing PTSD and the severity of symptoms in those with the disorder.

250

251 Taken together, our findings of associations of brighter light in the day and less light at night 252 as generally beneficial for psychiatric health point to the strengthening of circadian rhythms 253 as an underlying factor supporting more robust mental health. Patterns of bright daytime light 254 and low nighttime light can enhance the amplitude of the circadian clock strengthening the 255 clock's control of circadian rhythms throughout the brain and body. High amplitude rhythms 256 are also protective against perturbations from the disruptive effects of light at night. As modern humans spend ~90% of the day indoors<sup>34</sup>, our light exposure patterns are typically 257 less bright in the day and more bright at night than naturalistic patterns across our 258 evolutionary history<sup>35</sup>. These patterns of low daytime light and bright light at night dampen 259 260 the amplitude of circadian rhythms generated within the core circadian clock, leading to 261 downstream disorganization of rhythms throughout the brain and body. Targeting circadian 262 health is a highly promising means of promoting optimal general physiology, leading to more 263 robust mental and general health.

264

265 Though light at night can induce poor mood in the long term via circadian disruption (like a 266 perpetual jet lag), in the short term, light may be sought to acutely benefit mood. Light can 267 enhance mood acutely. We have recently shown that light can acutely inhibit activity of the amygdala in humans<sup>36</sup> (a brain region involved in negative emotionality), with brighter light 268 269 resulting in more suppression of amygdala activity. That study also showed that light dose-270 dependently enhanced the connectivity between the ventro-medial prefrontal cortex and amygdala, suggesting that light can enhance the control of negative emotionality. As poor 271 mood is generally higher in the night/early morning hours<sup>37</sup>, those experiencing such 272 challenges may seek light at these times to enhance mood. Though this would enhance mood 273 in the short term, it would lead to circadian disruption in the long term and potentially act to 274 275 perpetuate mental illness. Such motivations toward light represent a potential challenge for 276 promoting healthy light behaviors. However, these motivations to seek light may make the monitoring of self-exposure to light at night using wearables<sup>38,39</sup> a promising means of 277 278 tracking mood in patients.

279

This study is the first to report an analysis of objectively measured light exposure data from 280 281 the UK Biobank and is the largest examination of objective light exposure and mental health

282 to date. Across a broad range of psychiatric outcomes, our results demonstrate a powerful 283 impact of healthy light exposure patterns. These results suggest that promoting brighter days 284 and darker nights as a simple, freely available non-pharmacological intervention to enhance 285 mental health.

286

#### 287 Methods.

288

### 289 **Participants.** 290

291 The UK Biobank prospective general population cohort contains more than 502,000 UK residents (aged 37–73 years; ~54% women) recruited via National Health Service (NHS) 292 patient registers from 2006 to 2010. The study population is described in detail elsewhere<sup>40,41</sup>. 293 294 Participants provided detailed demographic, lifestyle, health, and employment information 295 via assessment and touch-screen questionnaire. Accelerometry and light data were measured 296 in a subset of more than 100,000 participants in 2013-2015 and approximately 160,000 297 participants completed an online Mental Health Questionnaire (MHO) in 2016-2017. Our 298 sample comprised participants whose activity and light data measurements passed rigorous quality control and had data on all covariates across regression models of increasing 299 300 adjustment. Characteristics of participants with low (quartiles 1 & 2) and high (quartiles 3 & 301 4) day and night light exposure groups are presented in Table 1. Participants who accepted the invitation to join the UK Biobank cohort provided written, informed consent and the UK 302 303 Biobank has generic ethical approval from the North West Multi-Center Research Ethics 304 Committee (ref 11/NW/03820).

305

#### 306 **Measurement of predictors**

307

308 In 2013, 240,000 UK Biobank participants were invited to wear an accelerometer for 7 days 309 as part of a physical activity and light monitoring study. Of these participants, 103,669 (43%) 310 accepted, and returned the accelerometer to UK Biobank after use. Participants who accepted 311 the invitation received a wrist-worn AX3 triaxial accelerometer (Axivity, Newcastle upon 312 Tyne, UK) with in-built light sensor (APDS9007 silicon photodiode sensor; spectral 313 sensitivity  $\lambda = 470-650$  nm) in the post and were asked to wear the device on their dominant 314 wrist continuously for 7 days, while continuing with their normal activities. At the end of the 315 7-day period, participants were instructed to return the accelerometer to UK Biobank using a 316 prepaid envelope.

317

318 Output current of the light sensor was extracted from the Axivity CWA files, down-sampled from 100Hz to 1Hz and converted from the logarithmic scale to approximate lux according to 319 320 the device manual ( $lux = 10^{(device output current/341)}$ ). Initial pre-processing of the light 321 data involved averaging 1Hz light samples into 10-second epochs. Participants' light data were then cleaned based on accelerometer non-wear. Non-wear was defined by GGIR 322 according to previously validated methodology<sup>42,43</sup>. Participants without valid days of sleep-323 wake data due to file corruption or consistent non-wear were also excluded. Of the 103,669 324 325 participants, 8,004 were excluded. The median (IQR) number of days of light data excluded 326 in this process per participant was 0.06 (0.00-0.01) and the median (IOR) number of valid 327 days per participant was 6.90 (5.95-6.99). Epochs were then smoothed with a median rolling window (10-minute window, 2-minute increments). Participants were then excluded if they 328 329 had unusually dark (percentage of data below  $1 \ln x > 80\%$ ), consistently bright (percentage of 330 data above 600lux >75%) or irregular light patterns (LRI > 100 or < 0) leaving 88,014 331 participants remaining.

## 332

Daily light profiles of participants were constructed by averaging epochs into forty-eight 30-333 334 min bins across the 24-hour period per study day and these bins were then averaged across 335 the study days to generate an average 24-hour light exposure profile per-participant (i.e. a 336 single 30-minute bin contained the average light exposure across the seven study days). 337 Participants with < 2 study days' worth of light data per 30-minute bin were excluded, 338 resulting in the loss of 18,301 bins of a possible 4,268,016 (0.43%) and 1,242 participants for 339 a final sample of 86,772.

340

341 Light exposure predictors were defined by factor analysis of the forty-eight 30-minute light bins across the 24-hour period to identify superordinate patterns in light exposure behavior in 342 343 the sample. Factor analysis supported the extraction of a two-factor structure (day, 7.30am-344 8.30pm; and night, 12.30am-6am; factor loadings  $\geq 0.5$ , varimax rotation) based on the scree 345 plot, the additional proportion of variance explained by each factor (>0.1) and the 346 independence of resultant factors. A three-factor structure including an evening (7.30pm-347 12.00am) factor was also explored, however, day and evening light were strongly correlated 348 (r = 0.76), indicating they were not independent and likely to misbehave in regression 349 models, and evening light bins had considerable cross-loading onto the day factor. As such, 350 the two-factor model was retained (cumulative proportion of variance explained = 0.56). Day 351 and night light variables were calculated by averaging light values across the respective time 352 bins.

353

Light exposure during the day had a small positive correlation with night light (r = 0.08, p < 0.08) 354 0.0001). Internal consistency of both day (Cronbach's  $\alpha = 0.98$ ) and night ( $\alpha = 0.93$ ) light 355 356 variables was very good. Test-retest reliability of day and night light measurements was 357 assessed in a subset of the actigraphy sample (n = 2.988) that completed a series of four 358 repeated actigraphy assessments. These repeated assessments occurred on average 3.23 years 359 (SD = 0.65) after the main assessment and took place over the course of a year with three 360 months between each measurement. A linear mixed-effects model with a crossed random 361 effect structure including participant, assessment, and time of day was used to estimate the 362 intra-class correlation (ICC). Light measurements showed good reliability, ICC = 0.803.

363

#### 364 **Measurement of outcomes**

365 Definition of case-control psychiatric outcome variables from the UK Biobank MHQ 366 followed guidelines established by Davis, Coleman <sup>44</sup>. Lifetime major depressive disorder 367 368 cases were defined according to the CIDI-SF lifetime depression module based on the DSM definition of major depressive disorder<sup>45</sup>. Cases were those who reported that they had at 369 370 least one core symptom of depression (persistent sadness or loss of interest), most or all of 371 the day on most or all days for a two-week period, with at least five depressive symptoms that 372 represent a change from usual occurring over the same time scale with some or a lot of 373 impairment. Individuals who reported a depression diagnosis were also recorded as cases (UKB 20544 & 20002). Controls were those who did not meet the above criteria and did not 374 375 report either of the canonical symptoms or a PHQ-9 score > 5. Lifetime generalized anxiety 376 disorder cases according to the CIDI-SF lifetime GAD module based on the DSM-IV definition of GAD<sup>45</sup>. Cases were those who reported excessive worrying about a number of 377 378 issues, occurring most days for six months and that were difficult to control, with three or 379 more somatic symptoms and functional impairment. Lifetime bipolar disorder cases were defined according to DSM-IV guidelines<sup>46,47</sup>. Cases were those who reported that they were 380 381 ever manic/hyper or irritable plus four other features of bipolar disorder for a duration of a

382 week or more with the symptoms causing significant problems or those who self-reported a 383 diagnosis of bipolar or mania (20544 = 10). Self-harm cases and controls were defined by yes 384 or no responses to the question "have you ever deliberately harmed yourself, whether or not 385 you meant to end your life?". PTSD was defined using the PTSD-Checklist-6 using a clinical case-control threshold of 13<sup>48</sup>. Lifetime psychotic experiences cases were defined using 386 participant responses to the MHO which were adapted from the CIDI<sup>49</sup>. Cases were those 387 388 who reported hearing an unreal voice, seeing an unreal vision, believing an unreal conspiracy. 389 believing an unreal communication or sign or had a diagnosis of schizophrenia or psychotic 390 illness (20544 = 2 or 3). Controls were those who did not meet the above criteria.

391

392 Continuous symptom severity scales for depression (PHQ-9; range = 0-27), anxiety (GAD-7, 393 range = 0-21) and PTSD (PCL-6, range = 6-29) were calculated by summing across the individual items in the MHQ to generate a total score<sup>48,50</sup>. A total well-being score was 394 calculated by summing across three items indexing general happiness (20458), happiness 395 396 with health (20459) and life meaningfulness (20460; range 3-17).

- 398 **Statistical analysis**
- 399

397

400 Associations between day and night light exposure and each of the psychiatric outcome 401 variables were examined in three separate regression models with increasing adjustment for 402 potential confounders. Each model included both day and night light categorical predictors to 403 examine their independent effects.

404

Due to the large positive skew in both day and night light variables (skewness > 1 for both) 405 406 and zero-inflation of the night light variable, both variables were converted into categorical 407 predictors by dividing them into four equal-sized quartiles ( $n_{01-04} = 21,693$ ) in ascending 408 brightness. Four bins were chosen to maximize the per-bin sample size while allowing for the 409 observation of non-linear effects.

410

411 The association between day and night light and case/control outcomes of lifetime major 412 depressive disorder, self-harm, GAD, PTSD, bipolar disorder, and psychotic experiences 413 were examined with multiple logistic regression. Odds ratios (OR) and their 95% confidence 414 intervals are reported. Linear regression was used for all continuous symptom severity scales 415 and standardized beta values are reported. For all models, a likelihood-ratio test was used as 416 an omnibus test of significance for the day and night light factors by comparing a model with 417 the given light variable included against a model without it. These associations were tested 418 hierarchically in three models with increasing adjustment for potential confounders. Model 1 419 examined the unadjusted association between day and night light and psychiatric outcomes. 420 Model 2 adjusted for age at the time of actigraphy, sex, ethnicity (white vs. non-white), 421 photoperiod as a measure of seasonality defined as the duration between sunrise and sunset at the beginning of the actigraphy assessment. Finally, model 3 additionally adjusted for 422 423 employment (employed vs. unemployed) and physical activity defined as overall acceleration 424 average in milligravity units (UKB field 90012). Data preprocessing for the physical activity measure was done by the UK Biobank accelerometer expert working group<sup>42</sup>. Coefficient 425 426 plots of the three models were constructed with inside and outside error bars reflecting one 427 standard error of the mean and the 95% confidence interval, respectively.

428

#### 429 **Role of the funding source**

The funder of the study played no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding authors have full access to the study data and final responsibility for the decision to submit for publication.

**Conflicts of interest** 

AJKP and SWC have received research funding from Delos and Versalux, and they are cofounders and co-directors of Circadian Health Innovations PTY LTD. SWC has also received research funding from Beacon Lighting and has consulted for Dyson. ACB: none; DPW: none; MKR: none; RS: none; JML: none; CV: none; PO: none.

### Data availability statement

481 **References.** 

482

Freeman D. Sheaves B. Waite F. Harvey AG. Harrison PJ. Sleep disturbance and 483 1. 484 psychiatric disorders. The lancet Psychiatry 2020; 7(7): 628-37.

485 Mure LS, Le HD, Benegiamo G, et al. Diurnal transcriptome atlas of a primate across 2. 486 major neural and peripheral tissues. Science 2018; 359(6381).

487 3. Winfree AT. The Geometry of Biological Time: Springer New York; 1980.

488 4. Souêtre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and 489 recovery: evidence for blunted amplitude as the main chronobiological abnormality. 490 Psychiatry research 1989; 28: 263-78.

491 Avery DH, Wildschiodtz G, Rafaelsen OJ. Nocturnal temperature in affective 5. 492 disorder. J Affect Disord 1982; 4(1): 61-71.

493 Szuba MP, Guze BH, Baxter LR, Jr. Electroconvulsive therapy increases circadian 6. 494 amplitude and lowers core body temperature in depressed subjects. Biological psychiatry 495 1997; 42(12): 1130-7.

496 Coleman MY, McGlashan EM, Vidafar P, Phillips AJK, Cain SW. Advanced 7. 497 melatonin onset relative to sleep in women with unmedicated major depressive disorder. 498 Chronobiol Int 2019; 36(10): 1373-83.

499 Emens J, Lewy A, Kinzie JM, Arntz D, Rough J. Circadian misalignment in major 8. 500 depressive disorder. Psychiatry Res 2009; 168(3): 259-61.

501 Hasler BP, Buysse DJ, Kupfer DJ, Germain A. Phase relationships between core 9. 502 body temperature, melatonin, and sleep are associated with depression severity: further 503 evidence for circadian misalignment in non-seasonal depression. Psychiatry Res 2010; 504 **178**(1): 205-7.

505 Harvey A. Sleep and circadian functioning: critical mechanisms in the mood 10. 506 disorders? Annual review of clinical psychology 2011; 7: 297-319.

507 11. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments 508 and treatment implications. European neuropsychopharmacology : the journal of the 509 European College of Neuropsychopharmacology 2008; 18: 701-11.

510 Li JZ, Bunney BG, Meng F, et al. Circadian patterns of gene expression in the human 12. 511 brain and disruption in major depressive disorder. Proceedings of the National Academy of 512 Sciences of the United States of America 2013; 110(24): 9950-5.

513 Jewett ME, Kronauer RE, Czeisler CA. Phase-amplitude resetting of the human 13. 514 circadian pacemaker via bright light: a further analysis. J Biol Rhythms 1994; 9(3-4): 295-314. 515

516 14. Phillips AJK, Vidafar P, Burns AC, et al. High sensitivity and interindividual variability 517 in the response of the human circadian system to evening light. Proc Natl Acad Sci U S A 518 2019; 116(24): 12019-24.

519 15. McGlashan EM, Nandam LS, Vidafar P, Mansfield DR, Rajaratnam SMW, Cain SW. 520 The SSRI citalopram increases the sensitivity of the human circadian system to light in an 521 acute dose. Psychopharmacology (Berl) 2018; 235(11): 3201-9.

522 McGlashan EM, Drummond SPA, Cain SW. Evening types demonstrate reduced 16. 523 SSRI treatment efficacy. Chronobiol Int 2018; 35(8): 1175-8.

524 Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the 17. 525 treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 526 2005; 162(4): 656-62.

Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of Bright Light Treatment, Fluoxetine, 527 18. 528 and the Combination in Patients With Nonseasonal Major Depressive Disorder: A 529 Randomized Clinical Trial. JAMA Psychiatry 2016; 73(1): 56-63.

530 Burns AC, Saxena R, Vetter C, Phillips AJK, Lane JM, Cain SW. Time spent in 19. 531 outdoor light is associated with mood, sleep, and circadian rhythm-related outcomes: A 532 cross-sectional and longitudinal study in over 400,000 UK Biobank participants. J Affect 533 Disord 2021; 295: 347-52.

534 20. McCarthy MJ, Gottlieb JF, Gonzalez R, et al. Neurobiological and behavioral 535 mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary 536 literature review and agenda for future research from the ISBD task force on chronobiology. 537 Bipolar disorders 2022: 24(3): 232-63.

Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Rosenthal NE. Manic-depressive 538 21. 539 patients may be supersensitive to light. Lancet (London, England) 1981; 1(8216): 383-4.

540 22. Lewy AJ, Nurnberger JI, Jr., Wehr TA, et al. Supersensitivity to light: possible trait 541 marker for manic-depressive illness. The American journal of psychiatry 1985; 142(6): 725-7. 542 23. Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses of lithium 543 carbonate reduce melatonin light sensitivity in healthy volunteers. The international journal of 544 neuropsychopharmacology 2005; 8(2); 255-9.

545 24. Hallam KT, Olver JS, Norman TR. Effect of sodium valproate on nocturnal melatonin 546 sensitivity to light in healthy volunteers. Neuropsychopharmacology 2005; **30**(7): 1400-4.

547 25. Bailes HJ, Lucas RJ. Human melanopsin forms a pigment maximally sensitive to blue 548 light (lambdamax approximately 479 nm) supporting activation of G(q/11) and G(i/o) 549 signalling cascades. Proc Biol Sci 2013; 280(1759): 20122987.

550 26. Bullock B, McGlashan EM, Burns AC, Lu BS, Cain SW. Traits related to bipolar 551 disorder are associated with an increased post-illumination pupil response. Psychiatry Res 552 2019; 278: 35-41.

553 27. Henriksen TE, Skrede S, Fasmer OB, et al. Blue-blocking glasses as additive 554 treatment for mania: a randomized placebo-controlled trial. Bipolar Disord 2016; 18(3): 221-555 32.

556 Sandahl H, Baandrup L, Vindbjerg E, Jennum P, Carlsson J. Social zeitgebers and 28. 557 circadian dysrhythmia are associated with severity of symptoms of PTSD and depression in 558 trauma-affected refugees. European Archives of Psychiatry and Clinical Neuroscience 2021; 559 **271**(7): 1319-29.

560 McFarlane AC, Barton CA, Briggs N, Kennaway DJ. The relationship between urinary 29. 561 melatonin metabolite excretion and posttraumatic symptoms following traumatic injury. J 562 Affect Disord 2010; 127(1-3): 365-9.

563 Paul MA, Love RJ, Jetly R, et al. Blunted Nocturnal Salivary Melatonin Secretion 30. 564 Profiles in Military-Related Posttraumatic Stress Disorder. Frontiers in psychiatry 2019; 10: 565 882.

566 31. Youngstedt SD, Kline CE, Reynolds AM, et al. Bright Light Treatment of Combat-567 related PTSD: A Randomized Controlled Trial. *Military Medicine* 2022; **187**(3-4): e435-e44.

568 Agorastos A, Linthorst AC. Potential pleiotropic beneficial effects of adjuvant 32. 569 melatonergic treatment in posttraumatic stress disorder. Journal of pineal research 2016; 570 **61**(1): 3-26.

571 33. Burns AC, Phillips, A.J.K., Rutter, M.K., Saxena, R., Cain, S.W., Lane, J.M. Genome-572 wide gene by environment study of time spent in daylight and chronotype identifies emerging 573 genetic architecture underlying light sensitivity. medRxiv 2022; 2022.06.29.22277078.

574 34. Klepeis NE, Nelson WC, Ott WR, et al. The National Human Activity Pattern Survey 575 (NHAPS): a resource for assessing exposure to environmental pollutants. Journal of 576 Exposure Science & Environmental Epidemiology 2001; 11(3): 231-52.

Wright KP, Jr., McHill AW, Birks BR, Griffin BR, Rusterholz T, Chinoy ED. 577 35. 578 Entrainment of the human circadian clock to the natural light-dark cycle. Current biology : CB 579 2013; 23(16): 1554-8.

580 36. McGlashan EM, Poudel GR, Jamadar SD, Phillips AJK, Cain SW. Afraid of the dark: 581 Light acutely suppresses activity in the human amygdala. PLoS One 2021; 16(6): e0252350.

582 37. Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogues Clin Neurosci 583 2008; 10(3): 337-43.

584 Cain SW, McGlashan EM, Vidafar P, et al. Evening home lighting adversely impacts 38. 585 the circadian system and sleep. Sci Rep 2020; 10(1): 19110.

586 Mohamed A, Kalavally V, Cain SW, Phillips AJK, McGlashan EM, Tan CP. Wearable 39. 587 light spectral sensor optimized for measuring daily alpha-opic light exposure. Opt Express 588 2021; 29(17): 27612-27.

589 40. Collins R. What makes UK Biobank special? The Lancet 2012; 9822(379): 1173-4.

590 Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for 41. 591 identifying the causes of a wide range of complex diseases of middle and old age. PLOS 592 Medicine 2015: 12(3): e1001779.

Dohertv A, Jackson D, Hammerla N, et al. Large Scale Population Assessment of 593 42. 594 Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. PLOS ONE 595 2017; 12(2): e0169649.

596 Windred DP, Jones SE, Russell A, et al. Objective assessment of sleep regularity in 43. 597 60 000 UK Biobank participants using an open-source package. Sleep 2021; 44(12).

598 Davis KAS, Coleman JRI, Adams M, et al. Mental health in UK Biobank -44. 599 development, implementation and results from an online questionnaire completed by 157 600 366 participants: a reanalysis. BJPsych open 2020; 6(2): e18.

601 Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H-U. The World Health 45. 602 Organization Composite International Diagnostic Interview short-form (CIDI-SF). 603 International Journal of Methods in Psychiatric Research 1998; 7(4): 171-85.

604 Carvalho AF, Takwoingi Y, Sales PMG, et al. Screening for bipolar spectrum 46. 605 disorders: A comprehensive meta-analysis of accuracy studies. Journal of Affective 606 Disorders 2015; 172: 337-46.

607 Cerimele JM, Chwastiak LA, Dodson S, Katon WJ. The prevalence of bipolar 47. 608 disorder in general primary care samples: a systematic review. General Hospital Psychiatry 609 2014; **36**(1): 19-25.

610 Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument 48. 611 in primary care. Behaviour Research and Therapy 2005; 43(5): 585-94.

612 Nuevo R, Chatteriji S, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. The 49. 613 Continuum of Psychotic Symptoms in the General Population: A Cross-national Study. 614 Schizophrenia Bulletin 2010; 38(3): 475-85.

615 Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire 50. 616 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. General Hospital 617 Psychiatry 2010; 32(4): 345-59.

13

618

619

620

It is made available under a

641 **Figures** 





Figure 1. Coefficients plot for day and night-time light associations with (A) major 645 depressive disorder, (B) self-harm behavior, (C) generalized anxiety disorder, (D) PTSD, (E) 646 bipolar disorder and (F) psychotic experiences. Coefficients represent the odds ratios  $\pm$  the 647 SEM (inner error bar) and 95% CI (outer error bar) for each quartile of day and night light 648 exposure relative to the low light (Q1) referent. Three models are presented with increasing 649 650 adjustment for confounders: Model 1 (green) is unadjusted, Model 2 (blue) adjusts for age, 651 sex, ethnicity and photoperiod and Model 3 (red) additionally adjusts for employment and 652 physical activity.

- 653 654
- 655
- 656
- 657
- 658



Figure 2. Coefficients plot for day and night-time light associations with (A) PHQ-9 score, (B) wellbeing score, (C) GAD-7 score and (D) PCL-6 score. Coefficients represent the standardized betas ± the SEM (inner error bar) and 95% CI (outer error bar) for each quartile of day and night light exposure relative to the low light (Q1) referent. Three models are presented with increasing adjustment for confounders: Model 1 (green) is unadjusted, Model 2 (blue) adjusts for age, sex, ethnicity and photoperiod and Model 3 (red) additionally adjusts for employment and physical activity.

		Day light	Night light					
	Low Q1 & Q2 N=43386	High Q3 & Q4 N=43386	p value	Low Q1 & Q2 N=43387	High Q3 & Q4 N=43385	<i>p</i> value		
Age								
Mean (SD) 62.0 (7.94)		62.7 (7.71)	< 0.001	62.6 (7.86)	62.1 (7.79)	< 0.001		
Median [Min, Max]	Median [Min, 62.9 [43.6, 78.9] Max]			63.8 [43.5, 78.8]	63.2 [43.5, 78.9]			
Sex								
Female	25159 (58.0%)	24321 (56.1%)	< 0.001	25352 (58.4%)	24128 (55.6%)	< 0.001		
Male	18227 (42.0%)	19065 (43.9%)		18035 (41.6%)	19257 (44.4%)			
BMI								
Mean (SD)	26.7 (4.57)	26.7 (4.47)	0.212	26.3 (4.31)	27.1 (4.68)	< 0.001		
Median [Min, Max]	edian [Min, ax] 26.0 [12.1, 67.3]			25.7 [14.7, 58.4]	26.4 [12.1, 67.3]			
Missing	102 (0.2%)	83 (0.2%)		83 (0.2%)	102 (0.2%)			
White ethnicity	41679 (96.1%)	42226 (97.3%)	< 0.001	42233 (97.3%)	41672 (96.1%)	< 0.001		
Missing	150 (0.3%)	141 (0.3%)		136 (0.3%)	155 (0.4%)			
Employment								
No	15912 (36.7%)	17412 (40.1%)	< 0.001	17353 (40.0%)	15971 (36.8%)	< 0.001		
Yes	27474 (63.3%)	25974 (59.9%)		26034 (60.0%)	27414 (63.2%)			
Shiftwork								
No	39780 (91.7%)	40152 (92.5%)	< 0.001	40545 (93.4%)	39387 (90.8%)	< 0.001		
Yes	3606 (8.3%)	3234 (7.5%)		2842 (6.6%)	3998 (9.2%)			
Townsend								
Mean (SD)	-1.60 (2.89)	-1.94 (2.68)	< 0.001	-1.93 (2.69)	-1.61 (2.87)	< 0.001		
Median [Min, Max]	-2.34 [-6.26, 10.5]	-2.60 [-6.26, 9.89]		-2.60 [-6.26, 10.5]	-2.35 [-6.26, 9.99]			
Physical activity								
Mean (SD)	27.3 (7.89)	29.0 (8.16)	< 0.001	28.1 (7.97)	28.3 (8.17)	< 0.001		
Median [Min, Max]	26.4 [5.12, 69.3]	28.1 [4.83, 69.4]		27.1 [4.83, 69.2]	27.3 [5.12, 69.4]			
Missing	39 (0.1%)	94 (0.2%)		60 (0.1%)	73 (0.2%)			
Photoperiod								
Mean (SD)	10.9 (2.87)	14.1 (2.58)	< 0.001	12.4 (3.06)	12.6 (3.28)	< 0.001		
Median [Min, Max]	10.2 [7.47, 17.0]	14.8 [7.47, 17.0]		12.4 [7.47, 17.0]	12.8 [7.47, 17.0]			

 Table 1. Demographic characteristics of participants by low and high day and night light exposure

	Model 1 OR (95% CI)				Model 2 aOR (95% CI)*				Model 3 aOR (95% CI) <sup>†</sup>			
Night light	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$
Major depressive disorder	1.05 (1.00 – 1.11)	1.17 (1.11 – 1.24)	1.28 (1.22 – 1.36)	<0.0001	1.04 (0.98 – 1.09)	1.17 (1.11 – 1.24)	1.32 (1.25 – 1.39)	<0.0001	1.04 (0.98 – 1.10)	1.18 (1.12 – 1.25)	1.30 (1.23 - 1.38)	<0.0001
Self-harm	1.02 (0.91 – 1.14)	1.03 (0.92 – 1.15)	1.28 (1.15 – 1.42)	<0.0001	0.99 (0.88 – 1.10)	0.99 (0.88 – 1.11)	1.28 (1.15 – 1.43)	<0.0001	0.99 (0.88 – 1.11)	1.00 (0.89 – 1.12)	1.27 (1.14 – 1.42)	<0.0001
Generalized anxiety disorder	1.10 (0.99 – 1.21)	1.22 (1.10 - 1.35)	1.23 (1.11 - 1.36)	<0.0001	1.06 (0.96 – 1.18)	1.18 (1.07 – 1.31)	1.23 (1.11 – 1.36)	0.0002	1.07 (0.97 – 1.19)	1.20 (1.08 – 1.33)	1.23 (1.11 – 1.36)	0.0001
PTSD	1.03 (0.93 – 1.13)	1.19 (1.08 – 1.31)	1.35 (1.23 – 1.48)	<0.0001	1.00 (0.90 – 1.11)	1.15 (1.04 – 1.27)	1.35 (1.22 – 1.48)	<0.0001	1.00 (0.91 – 1.11)	1.16 (1.05 - 1.29)	1.34 (1.22 – 1.48)	<0.0001
Bipolar Disorder	1.15 (0.98 – 1.36)	1.17 (0.99 – 1.38)	1.25 (1.06 - 1.47)	0.06	1.11 (0.94 – 1.31)	1.11 (0.94 – 1.31)	1.21 (1.02 – 1.43)	0.18	1.11 (0.94 – 1.31)	1.12 (0.95 – 1.32)	1.20 (1.02 - 1.42)	0.18
Psychotic Experiences	1.05 (0.95 – 1.17)	1.17 (1.05 – 1.29)	1.21 (1.10 – 1.35)	0.0005	1.03 (0.93 – 1.15)	1.13 (1.02 – 1.26)	1.22 (1.10 - 1.35)	0.0004	1.04 (0.93 – 1.15)	1.14 (1.03 – 1.27)	1.21 (1.09 – 1.34)	0.0009

Table 2. Associations between night light exposure and psychiatric outcomes

Note: logistic regression was used for all outcomes and odds ratios (ORs) are presented with their 95% confidence intervals for each ascending night light quartile relative to the low light (Q1) referent. Model 1 is unadjusted. \*Model 2 adjusted for age, sex, ethnicity, and photoperiod as a measure of seasonality. <sup>†</sup>Model 3 is additionally adjusted for employment and physical activity. <sup>‡</sup>Likelihood ratio tests (LRT) were done as an omnibus test of significance for the night light factor. Bolded coefficients indicate significance at the .05 level.

	Model 1 OR (95% CI)				Model 2 aOR (95% CI)*				Model 3 aOR (95% CI) <sup>†</sup>			
Day light	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT $p^{\ddagger}$
Major depressive disorder	0.94 (0.90 - 1.00)	0.91 (0.86 - 0.96)	0.80 (0.76 - 0.85)	<0.0001	0.91 (0.86 - 0.97)	0.85 (0.80 - 0.90)	0.75 (0.70 - 0.80)	<0.0001	0.93 (0.88 - 0.99)	0.88 (0.83 - 0.93)	0.81 (0.76 - 0.87)	<0.0001
Self-harm	0.87 (0.78 - 0.97)	0.81 (0.73 - 0.90)	0.77 (0.69 - 0.85)	<0.0001	0.83 (0.75 - 0.93)	0.76 (0.67 - 0.85)	0.71 (0.63 - 0.81)	<0.0001	0.85 (0.76 - 0.94)	0.78 (0.70 - 0.88)	0.76 (0.67 – 0.87)	0.0001
Generalized anxiety disorder	1.00 (0.90 – 1.10)	0.94 (0.85 – 1.03)	0.91 (0.82 – 1.00)	0.14	0.98 (0.89 – 1.09)	0.91 (0.82 – 1.02)	0.91 (0.81 – 1.03)	0.28	0.99 (0.90 – 1.10)	0.93 (0.84 – 1.04)	0.96 (0.85 – 1.09)	0.61
PTSD	0.94 (0.86 – 1.04)	0.92 (0.83 – 1.01)	0.80 (0.73 - 0.89)	0.0001	0.91 (0.83 – 1.00)	0.86 (0.77 - 0.95)	0.75 (0.67 - 0.84)	<0.0001	0.93 (0.85 - 1.03)	0.89 (0.81 - 0.99)	0.82 (0.73 - 0.92)	0.01
Bipolar disorder	0.88 (0.75 – 1.04)	0.95 (0.81 – 1.12)	0.81 (0.69 - 0.95)	0.06	0.86 (0.73 – 1.02)	0.94 (0.80 – 1.12)	0.81 (0.67 - 0.99)	0.10	0.87 (0.74 – 1.03)	0.97 (0.81 – 1.15)	0.86 (0.70 – 1.05)	0.22
Psychotic Experiences	1.00 (0.91 – 1.10)	0.88 (0.79 - 0.97)	0.76 (0.69 - 0.85)	<0.0001	0.95 (0.86 – 1.06)	0.79 (0.71 - 0.88)	0.65 (0.57 - 0.74)	<0.0001	0.97 (0.88 – 1.07)	0.81 (0.73 - 0.91)	0.69 (0.61 - 0.79)	<0.0001

Table 3. Associations between day light exposure and psychiatric outcomes

Note: logistic regression was used for all outcomes and odds ratios (ORs) are presented with their 95% confidence intervals for each ascending day light quartile relative to the low light (Q1) referent. Model 1 is unadjusted. \*Model 2 adjusted for age, sex, ethnicity, and photoperiod as a measure of seasonality. <sup>†</sup>Model 3 is additionally adjusted for employment and physical activity. <sup>‡</sup>Likelihood ratio tests (LRT) were done as an omnibus test of significance for the day light factor. Bolded coefficients indicate significance at the .05 level.